Martin J. Gilligan
Corporate Officer/Principal bei PHATHOM PHARMACEUTICALS, INC.
Profil
Martin J.
Gilligan is currently the Chief Commercial Officer at Phathom Pharmaceuticals, Inc. Previously, he worked as the VP-Inflammation & Immunology at Celgene Corp.
He holds an MBA from Rutgers State University of New Jersey and an undergraduate degree from Providence College.
Aktive Positionen von Martin J. Gilligan
| Unternehmen | Position | Beginn |
|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 06.01.2020 |
Ehemalige bekannte Positionen von Martin J. Gilligan
| Unternehmen | Position | Ende |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
Ausbildung von Martin J. Gilligan
| Rutgers State University of New Jersey | Masters Business Admin |
| Providence College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
